112 related articles for article (PubMed ID: 26158282)
1. Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir.
Cusato J; Allegra S; De Nicolò A; Boglione L; Fatiguso G; Mohamed Abdi A; Cariti G; Di Perri G; D'Avolio A
J Pharm Pharm Sci; 2015; 18(2):171-6. PubMed ID: 26158282
[TBL] [Abstract][Full Text] [Related]
2. Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics.
Cusato J; Allegra S; De Nicolò A; Boglione L; Fatiguso G; Abdi AM; Cariti G; Di Perri G; D'Avolio A
Int J Antimicrob Agents; 2015 Jun; 45(6):657-61. PubMed ID: 25836019
[TBL] [Abstract][Full Text] [Related]
3. ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy.
Cusato J; Allegra S; De Nicolò A; Boglione L; Fatiguso G; Cariti G; Ciancio A; Smedile A; Strona S; Troshina G; Rizzetto M; Di Perri G; D'Avolio A
Biomed Pharmacother; 2015 Feb; 69():63-9. PubMed ID: 25661339
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response.
Furusyo N; Ogawa E; Murata M; Toyoda K; Ohnishi H; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Kainuma M; Okada K; Hayashi J
J Antimicrob Chemother; 2014 Feb; 69(2):483-90. PubMed ID: 24092661
[TBL] [Abstract][Full Text] [Related]
5. Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation.
Farnik H; Zimmermann T; Herrmann E; Bechstein WO; Kronenberger B; Galle PR; Labocha S; Ferreiros N; Geisslinger G; Zeuzem S; Sarrazin C; Welker MW
Liver Int; 2015 Jan; 35(1):176-83. PubMed ID: 24649882
[TBL] [Abstract][Full Text] [Related]
6. Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.
Gutierrez-Valencia A; Ruiz-Valderas R; Ben-Marzouk-Hidalgo OJ; Torres-Cornejo A; Espinosa N; Castillo-Ferrando JR; Viciana P; Lopez-Cortes LF
Antimicrob Agents Chemother; 2015; 59(6):3257-62. PubMed ID: 25801562
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
8. A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir.
D'Avolio A; De Nicolò A; Agnesod D; Simiele M; Mohamed Abdi A; Dilly Penchala S; Boglione L; Cariti G; Di Perri G
J Pharm Biomed Anal; 2013 May; 78-79():217-23. PubMed ID: 23501442
[TBL] [Abstract][Full Text] [Related]
9. UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells.
De Nicolò A; Abdi AM; Boglione L; Baiett L; Allegra S; Di Perri G; D'Avolio A
J Pharm Biomed Anal; 2015 Nov; 115():443-9. PubMed ID: 26291788
[TBL] [Abstract][Full Text] [Related]
10. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.
Bodeau S; Nguyen-Khac E; Solas C; Bennis Y; Capron D; Duverlie G; Brochot E
J Clin Pharmacol; 2015 May; 55(5):517-24. PubMed ID: 25535910
[TBL] [Abstract][Full Text] [Related]
11. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner.
De Nicolò A; Boglione L; Ciancio A; Cusato J; Strona S; Cardellino CS; Abdi AM; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G; D'Avolio A
Antiviral Res; 2014 Sep; 109():7-14. PubMed ID: 24956496
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
Ogawa E; Furusyo N; Kajiwara E; Nomura H; Kawano A; Takahashi K; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J
J Gastroenterol Hepatol; 2015 Dec; 30(12):1759-67. PubMed ID: 26095167
[TBL] [Abstract][Full Text] [Related]
13. Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study.
Rubin RA; Russo MW; Brown KA; Fontana RJ; Levitsky J; Vargas H; Yoshida EM; Brown RS
Exp Clin Transplant; 2018 Apr; 16(2):182-190. PubMed ID: 27855589
[TBL] [Abstract][Full Text] [Related]
14. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
15. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir.
Boglione L; De Nicolò A; Cusato J; Cariti G; Di Perri G; D'Avolio A
J Viral Hepat; 2014 Apr; 21(4):260-3. PubMed ID: 24597694
[TBL] [Abstract][Full Text] [Related]
16. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms.
D'Avolio A; Carcieri C; Cusato J; Simiele M; Calcagno A; Allegra S; Sciandra M; Trentini L; Di Perri G; Bonora S
J Antimicrob Chemother; 2014 Nov; 69(11):3061-6. PubMed ID: 24997317
[TBL] [Abstract][Full Text] [Related]
17. Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection.
Farnik H; Ferreirós N; Labocha S; Geisslinger G; Zeuzem S; Sarrazin C; Vermehren J
Scand J Gastroenterol; 2014 Dec; 49(12):1473-9. PubMed ID: 25384840
[TBL] [Abstract][Full Text] [Related]
18. [Anti HCV drugs--ribavirin, telaprevir].
Sakamoto M; Enomoto N
Nihon Rinsho; 2012 Apr; 70(4):614-9. PubMed ID: 22568142
[TBL] [Abstract][Full Text] [Related]
19. Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Aouri M; Moradpour D; Cavassini M; Mercier T; Buclin T; Csajka C; Telenti A; Rauch A; Decosterd LA
Antimicrob Agents Chemother; 2013 Jul; 57(7):3147-58. PubMed ID: 23629707
[TBL] [Abstract][Full Text] [Related]
20. Telaprevir: changing the standard of care of chronic hepatitis C.
Rajani AK; Ravindra BK; Dkhar SA
J Postgrad Med; 2013; 59(1):42-7. PubMed ID: 23525057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
